Concepedia

Eric Mayoux

EM

Statistics

Publications

37

Citations

6.1K

H-Index

32

Active since

1987

Affiliations

Boehringer Ingelheim (Germany)(Current)

Inserm

Centre National de la Recherche Scientifique

VA San Diego Healthcare System

Hôpital Lariboisière

Eric Mayoux is an author at Boehringer Ingelheim (Germany) specializing in pharmacology, medicine, and diabetes mellitus.

Publications per year

1987–2020

37

Publications

37

CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

Ele Ferrannini, Michael Mark, Eric Mayoux · Diabetes Care · 2016 · 969 citations

, , +17

SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice

Liang Xu, Naoto Nagata, Mayumi Nagashimada et al. · EBioMedicine · 2017 · 493 citations · Full text

, , +17

SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice

Volker Vallon, Maria Gerasimova, Michael Rose et al. · American Journal of Physiology-Renal Physiology · 2013 · 477 citations

, , +17

Empagliflozin Increases Cardiac Energy Production in Diabetes

Subodh Verma, Sonia Rawat, Kim L. Ho et al. · JACC Basic to Translational Science · 2018 · 376 citations · Full text

, , +17

SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition

Issei Tomita, Shinji Kume, Sho Sugahara et al. · Cell Metabolism · 2020 · 362 citations · Full text

, , +16

1–5 of 37